RGCC Europe North and West
Location
SquareWorks, 17 Berkeley Square
Bristol, BS8 1HB, United Kingdom
Get In Touch
Our branch office is based in Bristol (UK) – we serve the region of North & West Europe.
Call Us
+44 117 302 1506
Email Us
Please use the contact form at the bottom
Hours
Mon-Fri: 09.30am-4.30pm
About RGCC Europe North & West Ltd
Dr Nicola Hembry BSc MBBS PgDip MRSB is the Director of RGCC Europe North and West Ltd which is the Branch Office in the North and West Region of Europe for RGCC International GmbH.
RGCC lnternational GmbH has laboratories around the world which specialize in personalized, precision medicine tests for cancer and viral illnesses, along with the manufacture of bespoke, tailored therapies for these conditions. RGCC are experts in liquid biopsy tests for circulating tumour cells (CTCs) plus associated biomarkers. Their approach reveals the genetic composition of cancers, enabling an individualised approach to therapy.
The business was launched in 2004 by genetics pioneer Dr Ioannis Papasotiriou MD PhD SCym. Dr Hembry pioneered the use of RGCC’s tests in the UK in 2005 and since 2009 has been co-director of RGCC Group’s branch office in the UK, Ireland and Scandinavia with Dr Papasotiriou.
RGCC Tests
RGCC’s liquid biopsy testing service, which includes advanced gene and genetic analysis, is designed to deliver three key outcomes in cancer:
• Identifying potential early indicators of previously undetected cancers
• Supporting the ongoing monitoring of confirmed cancer diagnoses
• Offering tailored guidance on both standard medical therapies and complementary natural/off label treatment options that may be suitable for each patient.
RGCC is accredited to detect circulating tumour cells (CTCs) at levels of 1 cell/25mls whole blood by flow cytometry and sorting. They specifically investigate the ‘cancer stem cell-like’ cell population as these reflect the driving entity of the disease. This investigation is via gene expression arrays and cell viability testing in 3D culture.
Learn more about the RGCC testing options at:https://rgcc-international.com
For further information, please use the contact form at the bottom of the site.
Onco-D-Clare
A cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear.
Peripheral blood mononuclear cells are isolated from blood samples, and gene expression analysis is performed in more than 90 genes. Their expression profile is then used for the classification of the sample as cancerous or healthy.
The Onco-D-Clare test provides individuals with essential information to help them make better-informed decisions about future health and well-being.
The test is clinically validated and highly accurate (≈93%).
InVyomma Plus
InVyomma Plus focuses on gut microbiome profiling, including analysis of short-chain fatty acids, and how they are associated with cancer.
It has been discovered that the microbiome is closely related to the occurrence and development of a variety of cancer types in the epithelial barrier and sterile tissues. Symbiotic ecosystems that inhabit the gut or other mucosa perform a role in both local and distal carcinogenesis.
On the one hand, the microbiome can provide toxic metabolites or carcinogenic products directly as cancer-transforming agents. Moreover, it can indirectly play a role in promoting cancer by the induction of inflammation or immunosuppression and can modulate the efficacy and toxicity of cancer therapy.
The InVyomma Plus test provides clinicians with essential information to help them make better-informed decisions about future treatment, health, and well-being.
InVyomma Plus requires 4 stool Collection Tubes, 2 for the gut microbiome profiling, and 2 for short-chain fatty acids analysis. The experimental/analysis period is approximately 2-3 weeks, and the results are ready in 2-4 weeks after the sample’s arrival in the laboratory facilities.
Onconomics
Onconomics provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.
The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of these two testing methods provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer.
Onconomics Plus
Onconomics Plus provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.
During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of the extensive tests provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used by clinicians to design personalised and targeted cancer therapies with the highest chances of success.
Onconomics Extracts
Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plant extracts are at attacking circulating cancer cells (CTCs).
Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of the most effective natural treatments that patients can use to treat their cancer, alongside conventional therapies.
Onconomics Extracts +
Onconomics Extracts+ provides highly detailed and accurate information about how effective specific natural substances and plant extracts are, as anticancer agents as well as the gene expression profile of genes, associated with fundamental biological processes. This includes processes such as angiogenesis, cell cycle regulation, self-repair, metastasis, apoptosis, proliferation etc.
Circulating tumor cells are isolated from a peripheral blood sample and then used for different assays. The results provide a comprehensive and highly personalized analysis of the most effective natural treatments that patients can use to treat their cancer, alongside conventional therapies.
Natural substances and extracts that are tested are divided into Class-I (Cytotoxic agents), Class-II (Immunostimulants / immunomodulators), and Class-III (PK inhibitors).
Oncocount
Oncocount detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning.
The test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).
Oncotrace
Oncotrail RGCC
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer.
During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype.
Oncotrail RGCC isn’t used as a primary diagnostic test to confirm a cancer diagnosis, but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.
ArrayCGH RGCC
The ArrayCGH RGCC test (Array Comparative Genomic Hybridisation) is used to identify chromosomal abnormalities in a patient that could lead to cancer.
During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. ArrayCGH RGCC can help clinicians better understand a patient’s genes, giving them a powerful tool in the fight against cancer.
ChemoSNiP
ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.
ChemoSNiP analyses a blood sample to identify single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents.
ChemoSNiP provides clinicians with a powerful insight into which drugs are most effective at treating cancer. The results provide a personalised analysis that can be used to provide the most effective combination of drugs and treatments available.
CAMBISeq
CAMBISeq is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.
The CAMBISeq – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy.
CAMBISeq is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.
Metastat
Immune-Frame
Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off.
The results of Immune-Frame can be used to analyse the status of a patient’s immune system, and to provide ongoing information about their health status. This information can be used by clinicians to advise on potential health risks a patient may face, and how these can be minimised.
More about RGCC
RGCC is a specialist medical genetics company and leading expert in the field of cancer genetics, liquid biopsy and chemosensitivity tests.
They provide personalised cancer genetics tests for doctors and patients worldwide in their ISO-accredited laboratories, which are equipped with the latest technology and specialised software for data analysis.
RGCC aims to detect any potential early signs of cancer, monitor existing cancers and produce a personalised profile of chemotherapy drugs and natural treatments that could benefit individual patients.
Further information about RGCC can be found by visiting the website below or contacting us through our form.
https://rgcc-international.com
Advantages of the RGCC Testing Methods
A key advantage of cancer blood tests is their ability to detect signs of cancer at an early stage of the disease. Often, certain biomarkers, such as specific proteins or changes in DNA, show up in the blood before clinical symptoms appear, earlier than they can be detected by MRI or PET. This enables early diagnosis, which in turn can improve the chances of successful treatment.
About Dr Nicola Hembry
BSc MBBS PgDip MRSB
Dr Nicola Hembry is a Medical Doctor with expertise in nutritional medicine, clinical oncology and psychology, Dr Hembry has dedicated nearly 30 years to integrative cancer care. She has spent 24 years in environmental and nutritional medicine and in 2011 completed a postgraduate qualification in clinical oncology.
Frequently Asked Questions
We answer some of the most common questions below - for any thing else please get in touch with our office.
Which tests support follow-ups and patient monitoring?
What else does RGCc Do?
In addition to pioneering personalized genetic testing for cancer, RGCC is deeply engaged in pharmaceutical research and development, operating from our cutting-edge facilities in Europe. Our esteemed scientists regularly publish peer-reviewed research, earning respect on a global scale.
Can brain tumours also be tested with a blood sample?
No, the blood-brain barrier prevents tumor cells from entering the bloodstream. Consequently, we cannot obtain or isolate any tumor cells from a blood sample. However, in such cases, cerebrospinal fluid can be used.
Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?
Certainly, patients with lymphoma or leukemia can utilize an RGCC test to measure the number of circulating tumor cells (CTC) they have.
What type of tests does rgcc offer?
RGCC provides a comprehensive range of tests designed to detect, analyze, and screen cancer cells. Our current portfolio includes tests capable of identifying potential early signs of cancer, monitoring diagnosed cancers, and offering personalized guidance on the most effective combinations of cancer treatments and therapies, including complementary approaches.
Contact us
Call Us
+44 117 302 1506
+44 7795 056056
Our Location
SquareWorks,
17 Berkeley Square,
Bristol,
BS8 1HB,
United Kingdom